Corteva (NYSE:CTVA) Given New $97.00 Price Target at Mizuho

Corteva (NYSE:CTVA) had its price target hoisted by Mizuho from $96.00 to $97.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho’s price target points to a potential upside of 12.87% from the company’s current price.

A number of other equities analysts have also issued reports on CTVA. BNP Paribas Exane increased their price target on Corteva from $74.00 to $77.00 in a research note on Wednesday, May 6th. Argus boosted their price objective on Corteva from $80.00 to $91.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Deutsche Bank Aktiengesellschaft upped their price objective on Corteva from $90.00 to $100.00 in a report on Monday, May 11th. Morgan Stanley raised their target price on Corteva from $84.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, May 28th. Finally, Wells Fargo & Company lifted their target price on Corteva from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Tuesday, April 21st. Thirteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Corteva has a consensus rating of “Moderate Buy” and an average price target of $88.95.

Corteva Stock Up 0.3%

CTVA stock opened at $85.94 on Tuesday. The firm’s 50-day moving average is $80.51 and its two-hundred day moving average is $77.74. The company has a market capitalization of $57.48 billion, a price-to-earnings ratio of 50.55, a price-to-earnings-growth ratio of 2.62 and a beta of 0.56. Corteva has a 52 week low of $60.53 and a 52 week high of $87.69. The company has a current ratio of 1.47, a quick ratio of 1.03 and a debt-to-equity ratio of 0.07.

Corteva (NYSE:CTVA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.32. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The business had revenue of $4.91 billion during the quarter, compared to analysts’ expectations of $4.64 billion. During the same period last year, the firm posted $1.13 earnings per share. The business’s revenue was up 11.0% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, analysts forecast that Corteva will post 3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Corteva

A number of hedge funds and other institutional investors have recently modified their holdings of CTVA. JPL Wealth Management LLC purchased a new stake in Corteva during the third quarter valued at about $25,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Corteva in the fourth quarter worth approximately $27,000. Bank of Jackson Hole Trust acquired a new stake in shares of Corteva during the fourth quarter valued at approximately $28,000. Cornerstone Financial Management LLC purchased a new stake in shares of Corteva in the 4th quarter valued at approximately $29,000. Finally, Elevation Wealth Partners LLC lifted its position in shares of Corteva by 334.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 339 shares of the company’s stock valued at $29,000 after acquiring an additional 261 shares in the last quarter. Institutional investors and hedge funds own 81.54% of the company’s stock.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid?2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.